DNA binding of TEA/ATTS domain factors is regulated by protein kinase C phosphorylation in human choriocarcinoma cells

被引:28
作者
Jiang, SW
Dong, MQ
Trujillo, MA
Miller, LJ
Eberhardt, NL
机构
[1] Mayo Clin, Dept Med, Div Endocrinol, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Biochem & Mol Biol, Div Endocrinol, Rochester, MN 55905 USA
[3] Mayo Clin, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA
关键词
D O I
10.1074/jbc.M010934200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Transcription enhancer factor 1 (TEF-1) controls the expression of a diverse set of genes. Previous studies implicated protein kinase C (PKC)-mediated signal transduction in modulating TEF function. We demonstrate that in human choriocarcinoma BeWo cells, the PKC activator 12-O-tetradecanoyl phorbol 13-acetate and PHC inhibitor bisindolylmaleimide reciprocally down- and up-regulate, respectively, TEF-mediated GGAATG core enhancer activity. In vitro TEF-1 phosphorylation with several PKC isozymes and phosphoamino acid analysis confirmed that TEF-1 is a potential PKC substrate. TEF-1(.)DNA complexes formed by BeWo nuclear extracts are supershifted by phosphoserine- and phosphothreonine- but not phosphotyrosine-specific antibodies, indicating that TEF-1 is phosphorylated in vivo at serine and threonine residues. The TEF-1 phosphorylation domain was localized to the third alpha -helix of the DNA binding domain and adjacent hinge region by phosphopeptide analysis. TEF-1 phosphorylation significantly reduced its DNA binding activity both in vitro and in vivo, providing a possible mechanism for the inhibitory action of PKC. Finally, BeWo cells contained abundant levels of gamma and delta PKC isoforms, and their overexpression resulted in even greater inhibition of GGAATG core enhancer activity after 12-O-tetradecanoyl phorbol 13-acetate treatment. These data strongly suggest that PKC-mediated phosphorylation is a key factor controlling TEF function.
引用
收藏
页码:23464 / 23470
页数:7
相关论文
共 49 条
[1]   PKC isoenzyme expression and cellular responses to phorbol ester in JEG-3 choriocarcinoma cells [J].
Bamberger, AM ;
Bamberger, CM ;
Wald, M ;
Jensen, K ;
Schulte, HM .
ENDOCRINE, 1997, 6 (02) :111-116
[2]   ACTIVATION OF PROTEIN-KINASE-C DECREASES PHOSPHORYLATION OF C-JUN AT SITES THAT NEGATIVELY REGULATE ITS DNA-BINDING ACTIVITY [J].
BOYLE, WJ ;
SMEAL, T ;
DEFIZE, LHK ;
ANGEL, P ;
WOODGETT, JR ;
KARIN, M ;
HUNTER, T .
CELL, 1991, 64 (03) :573-584
[3]  
Cabell CH, 1996, P ASSOC AM PHYSICIAN, V108, P37
[4]  
CARTER AN, 1997, CURRENT PROTOCOLS MO
[5]   DNA binding by cut homeodomain proteins is down-modulated by casein kinase II [J].
Coqueret, O ;
Martin, N ;
Bérubé, G ;
Rabbat, M ;
Litchfield, DW ;
Nepveu, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (05) :2561-2566
[6]   COMPARISON OF ABILITY OF PROTEIN-KINASE-C INHIBITORS TO ARREST CELL-GROWTH AND TO ALTER CELLULAR PROTEIN-KINASE-C LOCALIZATION [J].
COURAGE, C ;
BUDWORTH, J ;
GESCHER, A .
BRITISH JOURNAL OF CANCER, 1995, 71 (04) :697-704
[7]   THE HELA-CELL PROTEIN TEF-1 BINDS SPECIFICALLY AND COOPERATIVELY TO 2 SV40 ENHANCER MOTIFS OF UNRELATED SEQUENCE [J].
DAVIDSON, I ;
XIAO, JH ;
ROSALES, R ;
STAUB, A ;
CHAMBON, P .
CELL, 1988, 54 (07) :931-942
[8]   PHORBOL ESTER-INDUCED AMINO-TERMINAL PHOSPHORYLATION OF HUMAN JUN BUT NOT JUNB REGULATES TRANSCRIPTIONAL ACTIVATION [J].
FRANKLIN, CC ;
SANCHEZ, V ;
WAGNER, F ;
WOODGETT, JR ;
KRAFT, AS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (15) :7247-7251
[9]   THE PHOSPHODIESTERASE INHIBITOR SQ-20006 SELECTIVELY BLOCKS MITOGEN ACTIVATION OF P70(S6K) AND TRANSITION TO S-PHASE OF THE CELL-DIVISION CYCLE WITHOUT AFFECTING THE STEADY-STATE PHOSPHORYLATION OF EIF-4E [J].
FROST, V ;
MORLEY, SJ ;
MERCEP, L ;
MEYER, T ;
FABBRO, D ;
FERRARI, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (44) :26698-26706
[10]   Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance [J].
Gekeler, V ;
Boer, R ;
Uberall, F ;
Ise, W ;
Schubert, C ;
Utz, I ;
Hofmann, J ;
Sanders, KH ;
Schachtele, C ;
Klemm, K ;
Grunicke, H .
BRITISH JOURNAL OF CANCER, 1996, 74 (06) :897-905